Insider Brief
- Lantern Pharma has publicly released predictBBB.ai™, an AI-driven platform that predicts blood-brain barrier permeability of small molecules with 94% accuracy, aiming to transform central nervous system drug development.
- The platform combines proprietary data from billions of molecular features with real-time ensemble algorithms, outperforming academic and commercial tools while establishing new industry standards for computational drug discovery.
- Protected by a global patent application, predictBBB.ai™ is positioned for broad adoption through a freemium model and integration with Lantern’s RADR® platform, supporting strategic partnerships and scalable AI-powered therapeutic development.
PRESS RELEASE — Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence company transforming oncology drug discovery and development, today announced the public release of its AI module for predicting blood-brain barrier (BBB) permeability of small molecules with unprecedented accuracy and scalability – predictBBB.ai™. This critical advancement addresses one of pharmaceutical development’s most persistent challenges—that only 2-6% of small-molecule drugs can successfully cross the blood-brain barrier—while establishing new industry benchmarks for computational drug discovery platforms.
The transformative technology leverages billions of molecular feature data points across millions of compounds within Lantern’s proprietary molecular features data lake, enabling real-time ensemble algorithm processing that delivers 94% prediction accuracy with 95% sensitivity and 89% specificity. This represents a fundamental breakthrough in computational approaches to the development of molecules that need to reach the central nervous system (CNS), particularly significant given that the BBB technologies market is projected to expand from $1.4 billion in 2023 to $9.85 billion by 2032, reflecting urgent clinical demand for innovative and accessible solutions.
Establishing New Performance Standards Through Advanced, AI-Driven Computational Methodologies
Lantern’s BBB prediction module demonstrates exceptional technical superiority within the rapidly evolving AI drug discovery landscape. The platform currently holds five of the top eleven positions on the Therapeutic Data Commons Leaderboard, establishing clear technological leadership over competitive solutions including academic models and existing hard-to-access commercial platforms. Lantern’s ensemble methodology incorporating advanced molecular representation techniques, synthetic data augmentation, and proprietary feature engineering delivers superior performance through real-time processing capabilities that can analyze molecular structures instantaneously upon input. Detailed review of the algorithms and feature processing along with a demo of predictBBB™ can be accessed at www.predictBBB.ai and a white paper providing details into the development, training and overall architecture can also be accessed.
“This public release has the potential to be a paradigm shift in how pharmaceutical organizations and researchers approach CNS drug development,” stated Panna Sharma, Chief Executive Officer of Lantern Pharma. “Our technology transforms what has historically been one of drug discovery’s critical bottlenecks into a competitive advantage. By democratizing access to industry-leading BBB prediction capabilities through our freemium approach, we’re enabling researchers worldwide to accelerate therapeutic development while building strategic partnerships that drive innovation.”
Comprehensive Market Validation and Strategic Commercial Positioning
The broader AI drug discovery technology market’s expansion to $20.3 billion by 2030 underscores the critical importance of specialized computational tools and platforms for pharmaceutical development. Additionally, the consolidation trend exemplified by Recursion Pharmaceuticals’ $688 million acquisition of Exscientia reflects a trend towards more comprehensive AI platforms over point solutions. Lantern’s strategic positioning with both predictBBB.ai and the RADR AI platform addresses this dynamic through integrated capabilities that extend beyond BBB prediction to encompass dozens of additional molecular and clinical predictions and analytics critical to drug development success. The RADR™ platform and predictBBB.ai™ have been used in the advancement of several clinical stage molecules for both Lantern Pharma and its collaborators including Actuate Therapeutics and the CNS oncology programs for Starlight Therapeutics.
Revolutionary Technical Architecture Enabling Unprecedented Scalability
The platform’s foundational architecture represents years of systematic innovation in computational drug discovery methodologies. Built upon Lantern’s comprehensive molecular features data lake containing billions of data points across millions of compounds, the system employs sophisticated ensemble algorithms that process molecular SMILES inputs through real-time analysis combining multiple machine learning approaches including logistic regression, random forest, support vector machines, and deep neural networks. Lantern’s technical differentiation through proprietary feature engineering, advanced ensemble methodologies, and real-time processing capabilities positions the platform to capture market share and utility within this expanding and needed category of AI driven drug development. Lantern’s commercial-grade platform combines superior performance with enterprise-ready scalability and integration capabilities essential for pharmaceutical workflow implementation.
Strategic Freemium Model Accelerating Global Adoption and Partnership Development
The public release employs an innovative freemium strategy designed to accelerate adoption while creating pathways for strategic collaborations across the pharmaceutical ecosystem. This approach enables researchers to access foundational BBB prediction capabilities while demonstrating the platform’s comprehensive analytical power through progressively advanced features and functionality that are planned for future deployment. The rising adoption of subscription-based AI platforms for drug discovery validates the potential of this commercial model’s market alignment, while Lantern’s unique combination of proven performance, extensive molecular data foundation, and rapid feature deployment capabilities differentiates the offering from traditional licensing approaches.
“Our freemium strategy reflects deep understanding of how pharmaceutical organizations evaluate and adopt AI based computational tools,” continued Sharma. “By providing immediate access to industry-leading capabilities while continuously expanding functionality, we’re building relationships that evolve naturally into strategic partnerships focused on accelerating therapeutic development across multiple disease areas.”
Expanding Platform Capabilities Through Rapid Module Deployment
The BBB prediction module represents the inaugural release within Lantern’s comprehensive computational drug discovery platform roadmap. Recent advances in molecular property prediction using large language models and machine learning demonstrate the expanding possibilities for AI-driven pharmaceutical development. Lantern’s systematic approach to future module development and deployment will leverage the same foundational molecular data lake and ensemble methodologies that power the BBB prediction system, enabling rapid deployment of additional predictive capabilities addressing dozens of molecular properties critical to successful drug development. These forthcoming modules will encompass predictive, analytic and integrative tools for both specialized therapeutic area applications and general-purpose insights critical for most oncology drug development, creating a comprehensive platform for AI-driven, computational drug discovery.
Transformative Impact on Central Nervous System Therapeutic Development
The technology’s release addresses critical unmet needs within CNS drug development, where traditional approaches face failure rates 50% higher than other therapeutic areas with development costs exceeding those of cardiovascular therapeutics by 30%. By enabling accurate prediction of BBB permeability before expensive preclinical and clinical testing, the platform fundamentally transforms pharmaceutical development economics while accelerating therapeutic innovation for neurological disorders, brain cancers, and other CNS conditions.
Integration with Lantern’s RADR® AI platform enables comprehensive molecular assessment that extends beyond BBB permeability to encompass broader drug development considerations, creating synergistic analytical capabilities that enhance overall therapeutic development success rates. This integrated approach positions pharmaceutical partners to optimize compound selection, reduce development timelines, and improve probability of clinical success across CNS and oncology therapeutic programs.
Patent Protection and Competitive Differentiation
“We’re witnessing unprecedented demand for AI-driven solutions that deliver measurable impact on pharmaceutical development success rates,” noted Sharma. “Our BBB prediction module establishes the foundation for deeper partnerships that leverage our comprehensive platform capabilities to accelerate therapeutic development across diverse disease areas while maintaining the highest standards of scientific rigor and predictive accuracy.”
The technology benefits from comprehensive intellectual property protection through Lantern’s PCT patent application (PCT/US2024/019851), which received favorable search reports indicating no significant prior art. This strengthens the platform’s competitive positioning while providing pharmaceutical partners confidence in the technology’s proprietary nature and long-term viability.
The patent protection extends 20 years from filing date with expedited review initiated in the United States, ensuring market deployment advantages while protecting the innovative methodologies that enable superior predictive performance. This intellectual property foundation supports sustainable competitive advantages essential for long-term partnership development and platform expansion.
Future Collaborations & predictBBB.ai Enhancements
Lantern Pharma continues to advance predictBBB.ai through planned feature enhancements and expanded analytical capabilities while actively pursuing strategic partnerships with organizations committed to transforming CNS drug development. The company welcomes discussions with potential collaborators across pharmaceutical, biotechnology, and academic sectors who share Lantern’s vision of accelerating therapeutic innovation through advanced AI technologies.
